April 13, 2018 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina TruSight Oncology... Read more

June 3, 2017 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

NEW YORK and HILDEN, Germany, (June 3, 2017) – Bristol-Myers Squibb Company (NYSE: BMY) and QIAGEN(NASDAQ: QGEN; Frankfurt Prime Standard: QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as  predictive or prognostic tools for  use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in... Read more